Dosing completed in Phase 1 study of budoprutug subcutaneous formulation, with data expected in H1 2026 Budoprutug clinical trials ongoing in pMN, ITP, and SLE, with initial data from all three trials expected in H2 2026 Enrollment ongoing in CLYM116 Phase 1 healthy volunteer study, with initial data expected mid-2026 Strong financial position with cash […]
Category Archives: Pr Newswire
BARCELONA, Spain, March 5, 2026 /PRNewswire/ — At the Huawei Product & Solution Launch during MWC Barcelona 2026, Yuan Yuan, President of Huawei Data Storage Product Line, officially launched Huawei’s AI Data Platform. The platform integrates technologies of knowledge generation and retrieval, KV cache for inference acceleration, memory extraction and recall, as well as Unified […]
The Options Clearing Corporation (OCC®) has accepted delivery of two essential microservice-based risk systems from Vermiculus within a few months of implementation. STOCKHOLM, March 5, 2026 /PRNewswire/ — Vermiculus, global provider of clearing, trading and CSD technology, has delivered two VeriClear®-based and modular risk systems to The Options Clearing Corporation, the world’s largest equity derivatives […]
NANJING, China, March 5, 2026 /PRNewswire/ — Tuniu Corporation (NASDAQ: TOUR) (“Tuniu” or the “Company”), a leading online leisure travel company in China, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2025. Highlights for the Fourth Quarter of 2025 Net revenues in the fourth quarter of 2025 […]
SHANGHAI, March 5, 2026 /PRNewswire/ — ZKH Group Limited (“ZKH” or the “Company”) (NYSE: ZKH), a leading maintenance, repair and operations (“MRO”) procurement service platform in China, today announced that it will release its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2025, on Thursday, March 19, 2026, before the […]
PROVIDENCIALES, Turks and Caicos Islands, March 5, 2026 /PRNewswire/ — KuCoin, a leading global crypto platform built on trust, today announced “Trade New Futures & Share 1M Airdrop,” a KuCoin Futures campaign featuring a 1,000,000 USDT total reward pool designed to reward users who hold positions in newly listed futures contracts. The program accrues rewards […]
Pr Newswire
HealthRecon Connect Achieves HITRUST r2 Certification Demonstrating the Highest Level of Information Protection Assurance
05
Mar
Mar
HITRUST r2 Certification validates HealthRecon Connect’s commitment to strong cybersecurity and protecting sensitive healthcare data SOUTHLAKE, Texas, March 04, 2026 (GLOBE NEWSWIRE) — HealthRecon Connect, a leading provider of technology-enabled Revenue Cycle Management solutions to U.S. healthcare organizations, today announced that its Revenue Cycle Management platform and associated solutions — including Analytics & Dashboards, CDM […]
Pr Newswire
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome
05
Mar
Mar
–Results show that targeting the underlying cause of Dravet syndrome with zorevunersen may improve outcomes for people with this rare, devastating genetic neurodevelopmental disease– –Data support ongoing global Phase 3 EMPEROR study– BEDFORD, Mass. and CAMBRIDGE, Mass., March 04, 2026 (GLOBE NEWSWIRE) — Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein […]
05
Mar
Mar
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Carlsbad, California, March 04, 2026 (GLOBE NEWSWIRE) — Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF) announced today this it has amended an existing loan (the “Loan”) in the principal amount of US$1,600,000 plus accrued and […]
05
Mar
Mar
CHICAGO and FORT WORTH, Texas, March 04, 2026 (GLOBE NEWSWIRE) — Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that Dan Schmitt, President & CEO of the Company, […]